November 4, 2016
The Master Class XVII • 2016
Disclaimer
The recommendations provided from the authors were obtained on November 4, 2016. The opinions and recommendations do not necessarily accurately reflect the current state of affairs or the current advice the authors may choose to provide in the same circumstances. Please refer to the current guidelines or the Canadian Association of Gastroenterology (CAG) for up-to-date treatment options.
Learning Objectives
The educational objective of Mentoring in IBD is to increase awareness of current developments and best practices in inflammatory bowel disease (IBD) management, promote collaboration among Canadian gastroenterologists, and optimize treatment of IBD.
Participants in this program will be able to:
- Appraise the position of biosimilars in the therapeutic armamentarium for IBD today
- Examine the past, present and future management of IBD beyond anti-TNF-α agents
- Review the management of pyoderma gangrenosum and anti-TNF-α-induced dermatological complications in IBD
- Discuss mucosal healing in IBD with a focus on endoscopy
- Evaluate two clinical trials that will change practice in IBD
Getting Serious About Biosimilars
Presented by Stephen B. Hanauer
State-of-the-Art Plenary Presentation
Optimizing Management in IBD: Beyond Anti-TNFs
Presented by Remo Panaccione
State-of-the-Art Plenary Presentation
Management of Pyoderma Gangrenosum in IBD
Presented by Scott Walsh
State-of-the-Art Plenary Presentation
Anti-TNF-Induced Dermatological Complications in IBD
Presented by Hermenio Lima
State-of-the-Art Plenary Presentation
Optimizing Management in IBD: Mucosal Healing
Presented by Vipul Jairath
State-of-the-Art Plenary Presentation